Tae-Sung Koo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1459572/publications.pdf Version: 2024-02-01



TAE-SUNC KOO

#	Article	IF	CITATIONS
1	Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. Archives of Pharmacal Research, 2011, 34, 2059-2064.	2.7	26
2	Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies. Molecules, 2022, 27, 1977.	1.7	26
3	Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica, 2011, 41, 1100-1107.	0.5	25
4	Quantitative determination of enzalutamide, an antiâ€prostate cancer drug, in rat plasma using liquid chromatography–tandem mass spectrometry, and its application to a pharmacokinetic study. Biomedical Chromatography, 2014, 28, 1112-1117.	0.8	25
5	Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomedical Chromatography, 2011, 25, 1389-1394.	0.8	24
6	Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Archives of Pharmacal Research, 2015, 38, 2076-2082.	2.7	21
7	Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease. Experimental Eye Research, 2019, 180, 8-17.	1.2	21
8	Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance. International Journal of Nanomedicine, 2018, Volume 13, 7095-7106.	3.3	20
9	Development and Evaluation of Raloxifene-Hydrochloride-Loaded Supersaturatable SMEDDS Containing an Acidifier. Pharmaceutics, 2018, 10, 78.	2.0	20
10	Liquid chromatography–tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic study. Biomedical Chromatography, 2012, 26, 371-376.	0.8	18
11	Simultaneous quantification of methylene blue and its major metabolite, azure B, in plasma by LCâ€MS/MS and its application for a pharmacokinetic study. Biomedical Chromatography, 2014, 28, 518-524.	0.8	18
12	Hair-Growth-Promoting Effect of Conditioned Medium of High Integrin α6 and Low CD 71 (α6bri/CD71dim) Positive Keratinocyte Cells. International Journal of Molecular Sciences, 2015, 16, 4379-4391.	1.8	18
13	Comparison of Pharmacokinetics of Loxoprofen and its Active Metabolites After an Intravenous, Intramuscular, and Oral Administration of Loxoprofen in Rats: Evidence for Extrahepatic Metabolism. Journal of Pharmaceutical Sciences, 2005, 94, 2187-2197.	1.6	15
14	A highly sensitive fluorescent probe that quantifies transthyretin in human plasma as an early diagnostic tool of Alzheimer's disease. Chemical Communications, 2019, 55, 10424-10427.	2.2	15
15	Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors. European Journal of Medicinal Chemistry, 2016, 123, 777-787.	2.6	13
16	A Sensitive and Selective LC-MS Method for the Determination of Lurasidone in Rat Plasma, Bile, and Urine. Chromatographia, 2012, 75, 1117-1128.	0.7	12
17	The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers. Pharmaceutics, 2021, 13, 344.	2.0	12
18	Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3947-3952.	1.0	11

TAE-SUNG KOO

#	Article	IF	CITATIONS
19	Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122862.	1.2	11
20	Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs. Regulatory Toxicology and Pharmacology, 2016, 81, 387-396.	1.3	10
21	Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2018, 148, 397-409.	2.6	9
22	Development and validation of a liquid chromatography–tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats. Journal of Pharmaceutical and Biomedical Analysis, 2017, 137, 90-95.	1.4	8
23	Development of a liquid chromatography-tandem mass spectrometry method for assaying cenobamate in rat plasma. Journal of Liquid Chromatography and Related Technologies, 2018, 41, 992-997.	0.5	7
24	Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs. Journal of Veterinary Internal Medicine, 2019, 33, 531-535.	0.6	7
25	Discovery of non-LBD inhibitor for androgen receptor by structure-guide design. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3887-3890.	1.0	6
26	Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs. BMC Veterinary Research, 2018, 14, 291.	0.7	6
27	Quantification of clotiazepam in human plasma by gas chromatography–mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 834, 128-133.	1.2	5
28	Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. Journal of Pharmacy and Pharmacology, 2010, 58, 837-846.	1.2	5
29	Enhanced Solubility, In-Vitro Dissolution and Lipase Inhibition of a Self-Nanoemulsifying Drug Delivery System Containing Orlistat. Journal of Nanoscience and Nanotechnology, 2019, 19, 634-639.	0.9	5
30	Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112987.	1.4	4
31	Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors. Bioorganic and Medicinal Chemistry, 2022, 53, 116550.	1.4	4
32	Functional Impairment of Rat Taurine Transporter by Activation of Nitrogen Oxide through Superoxide. Drug Metabolism and Pharmacokinetics, 2012, 27, 286-293.	1.1	3
33	Liquid chromatography–tandem mass spectrometry of recombinant human extracellular superoxide dismutase (rhSOD3) in mouse plasma and its application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 590-597.	1.4	3
34	Design and Synthesis of a Novel 4-aryl-N-(2-alkoxythieno) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td ([2,3-b]p Cancer through G2/M Arrest. Pharmaceuticals, 2022, 15, 502.	oyrazine-3- 1.7	yl)-4-arylpiper 3
35	A validated HPLC–MS/MS method for the quantification of supinoxin in rat plasma and its application to pharmacokinetic study. Acta Chromatographica, 2017, 29, 463-468.	0.7	2
36	Effects of Angelica gigas extract on the oral pharmacokinetics of gefitinib in rats. Journal of Pharmaceutical Investigation, 2018, 48, 295-300.	2.7	2

TAE-SUNG KOO

#	Article	IF	CITATIONS
37	Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats. Xenobiotica, 2018, 48, 831-838.	0.5	1
38	Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs. BMC Veterinary Research, 2021, 17, 295.	0.7	1
39	Development of a LC–MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 123-127.	1.2	0
40	Effects of formulation types on pharmacodynamics of warfarin in patients with cerebral infarction and dysphagia. Clinical Pharmacology: Advances and Applications, 2019, Volume 11, 51-56.	0.8	0
41	Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats. Pharmaceutics, 2021, 13, 373.	2.0	0